CoChat

Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer

Open access
Yang, Jiawen, Mo, Jiajie, Dai, Juji, Ye, Chenqiao, Cen, Wei, Zheng, Xuzhi, Jiang, Lei, Ye, Lechi · 2021 · Cell Death & Disease

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Abstract

Cetuximab is approved for the treatment of metastatic colorectal cancer (mCRC) with RAS wild-type. Nevertheless, the prognosis remains poor and the effectiveness of cetuximab is limited in KRAS mutant mCRC. Recently, emerging evidence has shown that ferroptosis, a newly discovered form of nonapoptotic cell death, is closely related to KRAS mutant cells. Here, we further investigated whether cetuximab-mediated regulation of p38/Nrf2/HO-1 promotes RSL3-induced ferroptosis and plays a pivotal role in overcoming drug resistance in KRAS mutant colorectal cancer (CRC). In our research, we used two KRAS mutant CRC cell lines, HCT116 and DLD-1, as models of intrinsic resistance to cetuximab. The viability of cells treated with the combination of RSL3 and cetuximab was assessed by the CCK-8 and colony formation assays. The effective of cetuximab to promote RSL3-induced ferroptosis was investigated by evaluating lipid reactive oxygen species accumulation and the expression of the malondialdehyde and the intracellular iron assay. Cetuximab therapy contributed to regulating the p38/Nrf2/HO-1 axis, as determined by western blotting and transfection with small interfering RNAs. Cetuximab promoted RSL3-induced ferroptosis by inhibiting the Nrf2/HO-1 in KRAS mutant CRC cells, and this was further demonstrated in a xenograft nude mouse model. Our work reveals that cetuximab enhances the cytotoxic effect of RSL3 on KRAS mutant CRC cells and that cetuximab enhances RSL3-induced ferroptosis by inhibiting the Nrf2/HO-1 axis through the activation of p38 MAPK.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-021-04367-3

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Cetuximab enhances the cytotoxic effect of RSL3 on KRAS mutant CRC cells. A HCT116 and DLD-1 cells were treated with RSL3 (1 μM), cetuximab (100 μg/ml) or their combination for 24 h. The inhibitory effects were determined by the CCK-8 assay. B Cell morphology changes were observed by inverted light microscopy. Scale bar, 100 μm. C The colony formation with the indicated treatment was performed (left panel), and a histogram of colony numbers is shown (right panel). **P < 0.01.
Fig. 1 Cetuximab enhances the cytotoxic effect of RSL3 on KRAS mutant CRC cells. A HCT116 and DLD-1 cells were treated with RSL3 (1 μM), cetuximab (100 μg/ml) or their combination for 24 h. The inhibitory effects were determined by the CCK-8 assay. B Cell morphology changes were observed by inverted light microscopy. Scale bar, 100 μm. C The colony formation with the indicated treatment was performed (left panel), and a histogram of colony numbers is shown (right panel). **P < 0.01.CC BY · PubMed Central
Fig. 2 Cetuximab treatment enhances RSL3-induced ferroptosis in KRAS mutant CRC cells. A HCT116 and DLD-1 cells were treated with RSL3 (1 μM), cetuximab (100 μg/ml) or their combination for 24 h. The cellular lipid ROS level was analyzed by a flow cytometer. B HCT116 and DLD-1 cells were treated with RSL3 (1 μM), cetuximab (100 μg/ml) or their combination for 24 h. Intracellular MDA levels were measured by an MDA Assay Kit. C HCT116 and DLD-1 cells were treated with RSL3 (1 μM), cetuximab (100 μg/ml) or their combination for 24 h. Chelatable iron levels were determined using FerroOrange. Scale bar, 50 μm. D HCT116 and DLD-1 cells were treated with cetuximab (100 μg/ml) or RSL3 (1 μM) in the absence or presence of Fer-1 (1 μM) for 24 h, and cell viability was evaluated by the CCK-8 assay. E HCT116 and DLD-1 cells were treated with cetuximab (100 μg/ml) or RSL3 (1 μM) in combination with Z-VAD-FMK (10 μM), necrostatin-1 (10 μM) or 3-MA (60 μM) for 24 h, and cell viability was assessed by the CCK-8 assay. **P < 0.01; *P < 0.05; NS: no significance.
Fig. 2 Cetuximab treatment enhances RSL3-induced ferroptosis in KRAS mutant CRC cells. A HCT116 and DLD-1 cells were treated with RSL3 (1 μM), cetuximab (100 μg/ml) or their combination for 24 h. The cellular lipid ROS level was analyzed by a flow cytometer. B HCT116 and DLD-1 cells were treated with RSL3 (1 μM), cetuximab (100 μg/ml) or their combination for 24 h. Intracellular MDA levels were measured by an MDA Assay Kit. C HCT116 and DLD-1 cells were treated with RSL3 (1 μM), cetuximab (100 μg/ml) or their combination for 24 h. Chelatable iron levels were determined using FerroOrange. Scale bar, 50 μm. D HCT116 and DLD-1 cells were treated with cetuximab (100 μg/ml) or RSL3 (1 μM) in the absence or presence of Fer-1 (1 μM) for 24 h, and cell viability was evaluated by the CCK-8 assay. E HCT116 and DLD-1 cells were treated with cetuximab (100 μg/ml) or RSL3 (1 μM) in combination with Z-VAD-FMK (10 μM), necrostatin-1 (10 μM) or 3-MA (60 μM) for 24 h, and cell viability was assessed by the CCK-8 assay. **P < 0.01; *P < 0.05; NS: no significance.CC BY · PubMed Central
Fig. 3 Combination treatment with RSL3 and cetuximab inhibits Nrf2/HO-1 axis in KRAS mutant CRC cells. A The protein levels of Keap1, Nrf2 and HO-1 in HCT116 and DLD-1 cells were measured by western blotting after treatment with RSL3 (1 μM), cetuximab (100 μg/ml) or their combination for 24 h. B Knockdown of Nrf2 by siRNA reduced the expression of Nrf2 and the protein levels of Nrf2 and HO-1 after treatment with RSL3 (1 μM) for 24 h. C siRNA-mediated knockdown of Nrf2 increased the sensitivity of HCT116 and DLD-1 cells to RSL3. D–F The levels of MDA, lipid ROS and intracellular iron were measured in Nrf2-silenced HCT116 and DLD-1 cells pretreated with or without RSL3 (1 μM). Scale bar, 100 μm. **P < 0.01; *P < 0.05.
Fig. 3 Combination treatment with RSL3 and cetuximab inhibits Nrf2/HO-1 axis in KRAS mutant CRC cells. A The protein levels of Keap1, Nrf2 and HO-1 in HCT116 and DLD-1 cells were measured by western blotting after treatment with RSL3 (1 μM), cetuximab (100 μg/ml) or their combination for 24 h. B Knockdown of Nrf2 by siRNA reduced the expression of Nrf2 and the protein levels of Nrf2 and HO-1 after treatment with RSL3 (1 μM) for 24 h. C siRNA-mediated knockdown of Nrf2 increased the sensitivity of HCT116 and DLD-1 cells to RSL3. D–F The levels of MDA, lipid ROS and intracellular iron were measured in Nrf2-silenced HCT116 and DLD-1 cells pretreated with or without RSL3 (1 μM). Scale bar, 100 μm. **P < 0.01; *P < 0.05.CC BY · PubMed Central
Fig. 4 Cetuximab activates p38 MAPK and regulates the Nrf2/HO-1 axis. A Western blot analysis of p-p38, total p38, Nrf2 and HO-1 expression levels in HCT116 and DLD-1 cells incubated with cetuximab (100 μg/ml), SB202190 (1 μM) or cetuximab in combination with SB202190 for 24 h. B HCT116 and DLD-1 cells were treated with cetuximab (100 μg/ml) or RSL3 (1 μM) in the absence or presence of SB202190 (1 μM) for 24 h, and cell viability was assessed by the CCK-8 assay. C The protein levels of Nrf2 and HO-1 in HCT116 and DLD-1 cells or Nrf2 overexpressed HCT116 and DLD-1 cells treated with RSL3 (1 μM) combination with cetuximab (100 μg/ml) for 24 h. D HCT116 and DLD-1 cells with overexpression Nrf2 were treated with or without RSL3 (1 μM) combination with cetuximab (100 μg/ml) for 24 h. Cell viability was assessed by CCK-8 assays. E The protein level of HO-1 in HCT116 and DLD-1 cells or HO-1 overexpressed HCT116 and DLD-1 cells treated with RSL3 (1 μM) combination with cetuximab (100 μg/ml) for 24 h. F HCT116 and DLD-1 cells with overexpression HO-1 were treated with or without RSL3 (1 μM) combination with cetuximab (100 μg/ml) for 24 h. Cell viability was assessed by CCK-8 assays. G–H HCT116 and DLD-1 cells were treated with cetuximab (100 μg/ml) or RSL3 (1 μM) with or without t-BHQ (20 μM) or hemin (20 μM) for 24 h, and cell viability was assessed by the CCK-8 assay. **P < 0.01.
Fig. 4 Cetuximab activates p38 MAPK and regulates the Nrf2/HO-1 axis. A Western blot analysis of p-p38, total p38, Nrf2 and HO-1 expression levels in HCT116 and DLD-1 cells incubated with cetuximab (100 μg/ml), SB202190 (1 μM) or cetuximab in combination with SB202190 for 24 h. B HCT116 and DLD-1 cells were treated with cetuximab (100 μg/ml) or RSL3 (1 μM) in the absence or presence of SB202190 (1 μM) for 24 h, and cell viability was assessed by the CCK-8 assay. C The protein levels of Nrf2 and HO-1 in HCT116 and DLD-1 cells or Nrf2 overexpressed HCT116 and DLD-1 cells treated with RSL3 (1 μM) combination with cetuximab (100 μg/ml) for 24 h. D HCT116 and DLD-1 cells with overexpression Nrf2 were treated with or without RSL3 (1 μM) combination with cetuximab (100 μg/ml) for 24 h. Cell viability was assessed by CCK-8 assays. E The protein level of HO-1 in HCT116 and DLD-1 cells or HO-1 overexpressed HCT116 and DLD-1 cells treated with RSL3 (1 μM) combination with cetuximab (100 μg/ml) for 24 h. F HCT116 and DLD-1 cells with overexpression HO-1 were treated with or without RSL3 (1 μM) combination with cetuximab (100 μg/ml) for 24 h. Cell viability was assessed by CCK-8 assays. G–H HCT116 and DLD-1 cells were treated with cetuximab (100 μg/ml) or RSL3 (1 μM) with or without t-BHQ (20 μM) or hemin (20 μM) for 24 h, and cell viability was assessed by the CCK-8 assay. **P < 0.01.CC BY · PubMed Central
Fig. 5 Cetuximab enhances the inhibitory effects of RSL3 and RSL3-induced ferroptosis in vivo. A Schematic of the anticancer effect of the combination of RSL3 (5 mg/kg) and cetuximab (13 mg/kg) in a DLD-1 cell subcutaneous tumour model. B The tumour weights of excised tumours on day 19. C Excised tumours on day 19. D The tumour volume of each group was calculated every 3 days. E The body weight of each group was calculated every 3 days. F The level of MDA in excised tumours on day 19 was assayed. **P < 0.01.
Fig. 5 Cetuximab enhances the inhibitory effects of RSL3 and RSL3-induced ferroptosis in vivo. A Schematic of the anticancer effect of the combination of RSL3 (5 mg/kg) and cetuximab (13 mg/kg) in a DLD-1 cell subcutaneous tumour model. B The tumour weights of excised tumours on day 19. C Excised tumours on day 19. D The tumour volume of each group was calculated every 3 days. E The body weight of each group was calculated every 3 days. F The level of MDA in excised tumours on day 19 was assayed. **P < 0.01.CC BY · PubMed Central
Fig. 6 Cetuximab enhances RSL3-induced ferroptosis by inhibiting the Nrf2/HO-1 axis in vivo. A The protein levels of keap1, Nrf2 and HO-1 in tumour tissues were measured by western blotting. B The expression of Ki67, Keap1, Nrf2 and HO-1 were detected by immunohistochemical staining. Scale bar, 100 μm. **P < 0.01.
Fig. 6 Cetuximab enhances RSL3-induced ferroptosis by inhibiting the Nrf2/HO-1 axis in vivo. A The protein levels of keap1, Nrf2 and HO-1 in tumour tissues were measured by western blotting. B The expression of Ki67, Keap1, Nrf2 and HO-1 were detected by immunohistochemical staining. Scale bar, 100 μm. **P < 0.01.CC BY · PubMed Central
Fig. 7 Graphical abstract of the mechanism by which cetuximab enhances RSL3-induced ferroptosis by inhibiting the Nrf2/HO-1 axis through the activation of p38 MAPK. Cetuximab inhibited the Nrf2/HO-1 pathway via p38 MAPK activation and then regulated the sensitivity to RSL3 in KRAS mutant CRC cells.
Fig. 7 Graphical abstract of the mechanism by which cetuximab enhances RSL3-induced ferroptosis by inhibiting the Nrf2/HO-1 axis through the activation of p38 MAPK. Cetuximab inhibited the Nrf2/HO-1 pathway via p38 MAPK activation and then regulated the sensitivity to RSL3 in KRAS mutant CRC cells.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 301

Metadata

Authors
Yang, J., Mo, J., Dai, J., Ye, C., Cen, W., Zheng, X., Jiang, L., & Ye, L.
Affiliations
First Affiliated Hospital of Wenzhou Medical University (CN)
Corresponding author
  • Jiang, Lei
  • Ye, Lechi
Venue
Cell Death & Disease
Published
2021-11-13
Volume
12
Issue
11
Pages
1079-1079
ISSN
2041-4889 (ISSN-L)
OpenAlex
W3212627135
Cited by
300
References
52
Citations by year
2026: 42 · 2025: 65 · 2024: 79 · 2023: 79 · 2022: 35
FWCI
31.70
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Death and Disease (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81572291)
  • Natural Science Foundation of Zhejiang Province (LY19H160022)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords
cetuximab, ferroptosis, RSL3, p38 MAPK, KRAS mutation, colorectal cancer, drug resistance, combination therapy, lipid reactive oxygen species, intracellular iron, HCT116 cells, DLD-1 cells
MeSH terms
Cetuximab, Antineoplastic Agents, Immunological, Ferroptosis, Animals, Carbolines, Humans, Mice, Nude, Transfection, Colorectal Neoplasms, Signal Transduction, Proto-Oncogene Proteins p21(ras), Xenograft Model Antitumor Assays, Cell Line, Tumor, NF-E2-Related Factor 2, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer. https://app.cochat.ai/papers/10.1038/s41419-021-04367-3
The paper
Yang, J., Mo, J., Dai, J., Ye, C., Cen, W., Zheng, X., Jiang, L., & Ye, L. (2021). Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer. Cell Death & Disease. https://doi.org/10.1038/s41419-021-04367-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.